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Background: As the primary immune cells of the central nervous system, microglia contribute to development,
homeostasis, and plasticity of the central nervous system, in addition to their well characterized roles in the foreign
body and inflammatory responses. Increasingly, inappropriate activation of microglia is being reported as a component
of inflammation in neurodegenerative and neuropsychiatric disorders. The statin class of cholesterol-lowering drugs
have been observed to have anti-inflammatory and protective effects in both neurodegenerative diseases and ischemic
stroke, and are suggested to act by attenuating microglial activity.
Results: We sought to investigate the effects of simvastatin treatment on the secretory profile and phagocytic activity
of primary cultured rat microglia, and to dissect the mechanism of action of simvastatin on microglial activity. Simvastatin
treatment altered the release of cytokines and trophic factors from microglia, including interleukin-1-β, tumour
necrosis factor-α, and brain derived neurotrophic factor in a cholesterol-dependent manner. Conversely, simvastatin
inhibited phagocytosis in microglia in a cholesterol-independent manner.
Conclusions: The disparity in cholesterol dependence of cytokine release and phagocytosis suggests the two effects
occur through distinct molecular mechanisms. These two pathways may provide an opportunity for further refinement
of pharmacotherapies for neuroinflammatory, neurodegenerative, and neuropsychiatric disorders.
Keywords: Inflammation, Cholesterol, Mevalonate, PhagocytosisBackground
Microglia, the innate immune cells of the central nervous
system (CNS), carry out surveillance and are activated in
response to foreign bodies, infectious agents, and local
damage. On activation, microglia exhibit a spectrum of be-
haviours including initiation of the inflammatory response,
migration, proliferation, and phagocytosis of foreign parti-
cles and cellular debris, and modulation of the microenvir-
onment through synthesis and release of trophic and toxic
effectors. These curious cells are, however, far from quies-
cent in their ‘resting’, ramified, or surveilling state, playing
roles in development and maintenance of the CNS in-
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article, unless otherwise stated.modulating neuronal plasticity through synaptic prun-
ing, and maintaining homeostasis in concert with other
resident glial cells [1-7]. Unfortunately, inflammation
mediated by microglia has been implicated in an in-
creasing number of pathological conditions ranging
from acute injuries such as ischemic or hemorrhagic
stroke [8] and traumatic brain or spinal cord injury [9],
chronic inflammatory conditions such as multiple sclerosis
[10,11], neurodegenerative diseases including Alzheimer’s
[12], Parkinson’s [13], and vascular dementia [14], and even
neuropsychiatric disorders including major depressive dis-
order [7,15,16], schizophrenia [17-19], and bipolar disorder
[20]. The cumulative disease burden of neuroinflammatory
conditions involving microglia is substantial, and, as
many of these pathologies have unknown or poorly
understood etiology, targeting the common inflammatory
component represents a viable approach to improving im-
mediate health outcomes [21].d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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zyme A (HMG-CoA) reductase inhibitors have been one
of the most widely prescribed and successful classes of
drugs of all time. While statins were characterized for
their inhibition of cholesterol biosynthesis and lowering
of blood cholesterol levels, subsequent mechanistic stud-
ies have suggested much of their action in reducing risks
for cardiovascular disease are unrelated to cholesterol
levels, relating rather to pleiotropic effects including iso-
prenoid biosynthesis and subsequent protein prenylation
[22,23]. Studies of blood derived monocytes and macro-
phages have highlighted a number of anti-inflammatory
effects of statins including altered cytokine release and
phagocytic activity [24-29]. In the CNS statin treatment
has been suggested to delay the onset and slow the pro-
gression of Alzheimer’s disease and dementia [30-32],
and statin treatment after ischemic stroke and thromb-
olysis has recently been shown to improve functional
outcomes and reduce risk of neurological deterioration
and death [33]. Studies in rodents have shown statin
treatment improved outcomes in models of ischemic
stroke [34,35], intracerebral hemorrhage [36], traumatic
brain injury [37], and Alzheimer’s disease [38,39]. Des-
pite a wealth of evidence that statins directly modulate
macrophage function [24-29] and observation of changes
in microglial and inflammatory markers in the CNS after
statin treatment [35-39] studies of the direct effects of
statin treatment on microglia have been sparing, and
present conflicting data. In primary rodent microglial
cultures, lovastatin decreased release of inflammatory
mediators nitric oxide (NO), tumour necrosis factor-α
(TNFα), and interleukin-1β (Il1β) [40] and simvastatin
treatment decreased surface antigen expression including
major histocompatibility complex II (MHCII) and chemo-
kine receptor CXCR3 [41] while in primate microglial cul-
tures simvastatin increased secretion of cytokines (TNFα,
Il1β, interleukin-12, and interleukin-6) [42] and in rat hip-
pocampal slice cultures mevastatin treatment increased
cytokine release and surface antigen expression (TNFα,
cluster of differentiation[CD]-11b) [43]. In the current
study, we sought to analyse the direct effects and mechan-
ism of statin treatment on primary cultured microglia. We
demonstrate for the first time that simvastatin treatment
inhibits microglial phagocytosis and alters the release of
inflammatory mediators and growth factors via two inde-
pendent and separable molecular mechanisms.
Results
Simvastatin affects microglial secretion through
cholesterol-dependent mechanisms
Initial dose response experiments were performed to de-
termine the efficacy of simvastatin (from 1 μM to 80 μM)
at reducing microglial cholesterol, and showed 20 μM to
consistently reduce cellular cholesterol levels withoutadverse effects on cell viability (data not shown). This dose
is consistent with comparable studies in the literature
[43-46]. Treatment of primary microglia with 20 μM sim-
vastatin (Figure 1A-D), which decreased mean cellular
cholesterol by 18.0 ± 3.6%, was found to alter the release
of a number of microglial mediators into culture media,
including interleukin-1β (Il1β), tumour necrosis factor-α
(TNFα), and brain-derived neurotrophic factor (BDNF).
TNFα release was not detectable in microglia prior to acti-
vation with LPS, however simvastatin treatment signifi-
cantly increased the release of TNFα after LPS treatment
(Figure 1A). BDNF release was similarly affected by simva-
statin: treatment increased the release of BDNF selectively
from LPS-activated microglia (Figure 1B). Interestingly,
simvastatin did not have a significant effect on the re-
lease of NO from microglia (Figure 1C), and LPS-
activated microglia showed comparable increases in
NO release in all treatment groups. Simvastatin treat-
ment significantly decreased the basal release of IL1β
from microglia (Figure 1D), however IL1β release after
exposure to a potent inflammatory stimulus, bacterial
lipopolysaccharide (LPS), was not significantly different
between statin treatment and control (Figure 1D). Treat-
ment with simvastatin at the doses reported had no effect
on the viability of microglia as assessed using an MTT
assay (data not shown). While the overall effects of simva-
statin treatment on cytokine and trophic factor release are
mixed and dependent on activation state, with decreased
Il1β release from unstimulated microglia and increased
TNFα and BDNF release from LPS-activated microglia,
these data warranted further investigation into the mech-
anism of statin-mediated changes in secretory profile.
As statins have been proposed to affect both cholesterol-
dependent and cholesterol-independent (principally through
alterations in isoprenoid biosynthesis) cellular processes,
simvastatin treated microglia were supplemented with
cholesterol, solubilized in complex with 2-hydroxypropyl-
β-cyclodextrin (hpβcd-cholesterol), or mevalonolactone
(MEV), the lactone isomer of mevalonic acid, the immedi-
ate product of HMG-CoA reductase. Supplementation
of cholesterol is expected to affect only cholesterol-
dependent processes, while MEV supplementation is
expected to affect both cholesterol-dependent and inde-
pendent processes. The effects of simvastatin treatment
on TNFα and BDNF release were consistently reversed
by treatment with hpβcd-cholesterol: TNFα release
from LPS-activated microglia was decreased to that of
the control when cells were treated with simvastatin
followed by either hpβcd-cholesterol or MEV (Figure 1A),
while BDNF release was similarly decreased to the level of
control after treatment with simvastatin and hpβcd-
cholesterol, but not MEV (Figure 1B). Release of Il1β was
particularly sensitive to cholesterol, as hpβcd-cholesterol
treatment alone was able to decrease Il1β release in both
Figure 1 Statin treatment altered the secretory profile of microglia. Isolated rat microglial cultures were treated with 20 μM simvastatin for
24 h and subsequently activated with 1 μg/ml LPS overnight (18 h). For rescue experiments microglia were concurrently treated with 200 μM
MEV for 24 h or subsequently treated with 1 mM hpβcd-cholesterol 30 minutes prior to LPS stimulus. Media was collected and assayed for cytokine
release (Il1β and TNFα, A,D), neurotrophin release (BDNF, B), and nitric oxide secretion (C). All analyses were normalized to the total protein of the
corresponding cell lysate to control for cell viability. Asterisks represent P <0.05, 0.01, and 0.001 by 2-way ANOVA and Bonferroni’s post-hoc from N = 6
independent preparations.
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Co-treatment of LPS-activated microglia with simvastatin
and MEV was likewise able to decrease Il1β release from
LPS-activated microglia, but MEV treatment in LPS-
activated microglia alone did not affect Il1β release. While
these findings are confounded by the effects of cholesterol
alone on Il1β release, they are suggestive of a cholesterol-
dependent effect of simvastatin treatment.Simvastatin inhibits microglial phagocytosis through a
cholesterol-independent mechanism
Phagocytosis was assayed by immunofluorescent micro-
scopy of microglia previously incubated with green fluore-
scent carboxylate-modified latex beads [47] (Figure 2A). To
validate bead internalization in our assay system micro-
glia were processed for immunofluorescence using the
microglia-specific cytosolic marker ionized Ca2+-binding
Figure 2 Immunofluorescent measurement of phagocytosis. A – Representative image of microglia incubated with fluorescent latex beads
(green), immunolabelled for CD68 to identify the cell soma (red) and nuclei stained with DAPI (blue), scale bar represents 50 μm. B – Representative
confocal micrograph to demonstrate bead internalization. Microglia were incubated with fluorescent latex beads (green), immunolabelled for Iba1 to
visualize cytoplasmic volume (red), and nuclei stained with DAPI. Scale bar represents 25 μm, yellow line indicates the region projected orthogonally in C.
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(Figure 2B). A series of confocal z-stacks were acquired
and projected orthogonally to demonstrate that beads
were present within the cytosolic compartment (Figure 2C)
rather than simply adhering to the cell surface.
Simvastatin treatment significantly decreased phago-
cytosis in both the proportion of cells taking up latex
beads as well as the mean uptake per active phagocyte
(Figure 3A-B). This effect was observed in both un-
stimulated microglia and after LPS-activation, though
the effect was most pronounced in the unstimulated
group, and the difference in mean fluorescence did not
reach significance for the LPS-treated group. As with
previous assays of cytokine and trophic factor release,
we recovered cholesterol directly with hpβcd-cholesterol
to examine cholesterol-dependent contributions, and
used co-treatment with MEV to examine cholesterol-
independent contributions. The proportion of active
phagocytes remained significantly suppressed in cells
treated with simvastatin followed by hpβcd-cholesterol
without LPS stimulus, and remained significantly de-
creased relative to the cholesterol control group in LPS-
activated microglia (Figure 3A). Co-treatment with MEV
resulted in a significant increase in active phagocytes
and mean uptake per cell relative to the simvastatin
treated group without LPS stimulus (Figure 3A-B), and
after LPS-activation MEV co-treatment abolished the
significant difference from the respective control condi-
tion (but did not reach significance from either LPS-onlycontrol or simvastatin + LPS groups). No significant differ-
ences were observed in mean uptake per cell in the pres-
ence of LPS (Figure 3B). These data suggest that in the
presence or absence of an LPS stimulus microglial phago-
cytosis is sensitive to inhibition by simvastatin through
cholesterol-independent mechanisms.
Direct cholesterol manipulation affects microglial
secretion and phagocytosis
Given the observed sensitivity of microglial cytokine and
trophic factor release to changes in cholesterol induced
pharmacologically with simvastatin treatment, we sought
to examine the effects of direct manipulation of cellular
cholesterol levels using methyl-β-cyclodextrin (mβcd), a
water soluble reagent capable of removing and ‘chelating’
cholesterol from the plasma membrane. In contrast with
simvastatin treatment, which requires sustained treat-
ment to induce decreases in cellular cholesterol levels,
acute treatment with 4 mM mβcd decreased cellular
cholesterol rapidly, resulting in a 19.8 ± 5.4% reduction
within 30 minutes. As with simvastatin treatment, the
concentration of mβcd was titrated in initial experiments
to achieve consistent changes in cellular cholesterol level
without adverse effects on viability. Contrary to our find-
ings with simvastatin, treatment with 4 mM mβcd signifi-
cantly increased IL1β and BDNF release from unstimulated
microglia (Figure 4A,C). This increased release of Il1β was
similarly observed in cultures treated with mβcd and subse-
quently activated with LPS while a comparable, but not
Figure 3 Simvastatin treatment and cholesterol depletion
reversibly inhibit microglial phagocytosis. Isolated rat microglial
cultures were treated with simvastatin (A-B, treatments as in Figure 1).
200 μM MEV was added concurrently for 24 h, while 1 mM
hpβcd-cholesterol was added for 30 min at the end of the 24 h
simvastatin treatment. At the end of treatment cells were incubated
with carboxylate-modified green fluorescent latex beads (1x107/ml) for
3 h, fixed and immunolabelled for the microglia-specific antigen CD68.
Phagocytosis was quantified as the proportion of cells having taken up
at least 1 bead (proportion of microglia involved in phagocytosis; A)
and as the mean fluorescence per cell having taken up at least 1 bead
(mean uptake per active phagocyte; B). Asterisks represent P <0.05,
0.01, and 0.001 by 2-way ANOVA with Bonferroni’s post-hoc for N = 6
(A-B) independent culture preparations.
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observed following LPS treatment (Figure 4A, C). No
significant changes were observed in the release of
TNFα without LPS activation, while TNFα release from
LPS activated microglia was decreased in the mβcd
treated group (Figure 4B). As with simvastatin treat-
ment, no significant changes were observed for NO re-
lease (data not shown) from mβcd treated microglia
with or without LPS-activation. To determine the spe-
cificity of these effects, microglia were treated with
hpβcd-cholesterol to restore cholesterol back to the
plasma membrane. Surprisingly, treatment with hpβcd-
cholesterol after mβcd treatment decreased, but did not
restore Il1β release to baseline in unstimulated micro-
glia, yet markedly decreased Il1β release from LPS-activated microglia (Figure 4A). As was observed in the
simvastatin treated groups, cholesterol decreased Il1β
release from LPS-activated microglia independent of
mβcd treatment, in both the mβcd-treated and control
groups. In contrast, hpβcd-cholesterol treatment did
not affect TNFα release in any of the conditions tested
(Figure 4B), but was able to attenuate the release of
BDNF from both unstimulated and LPS activated
mβcd-treated microglia (Figure 4C). The failure of
cholesterol to restore TNFα release in mβcd- and LPS-
treated microglia suggests it may be a secondary effect
of the treatment not attributable to the changes in
cholesterol level. The effects of mβcd on BDNF and
Il1β are responsive to cholesterol level, though as Il1β
release from LPS-activated microglia was attenuated by
cholesterol even in the absence of prior mβcd treatment,
we infer that Il1β is particularly sensitive to cellular chol-
esterol levels, as treatment with hpβcd-cholesterol re-
sulted in an increase in mean cellular cholesterol of 77.8 ±
13.9% above control.
Interestingly, treatment of microglia with mβcd also
resulted in a significant reduction in the proportion of
active phagocytes and the mean uptake of latex beads
per phagocyte specifically in cells activated with LPS
(Figure 4D-E). Subsequent recovery of cholesterol by
hpβcd-cholesterol treatment restored phagocytosis to
that of control groups for both proportion of active
phagocytes and mean uptake per cell. Unlike Il1β re-
lease, supplementing cholesterol in control groups by
hpβcd-cholesterol treatment did not have any significant
effect on phagocytosis.
Discussion
In rat primary microglial cultures, statin treatment re-
sulted in reduced secretion of Il1β, and increased secre-
tion of TNFα and BDNF from activated microglia. The
altered release profile of microglia was largely reversed
by treatment with exogenous cholesterol, suggesting a
cholesterol-dependent mechanism. Treatment with mβcd,
a cholesterol depleting reagent, increased the release of
Il1β and BDNF from microglia and inhibited phagocytosis
in LPS-activated microglia in a manner that was reversed
by the addition of exogenous cholesterol. Conversely, sim-
vastatin treatment inhibited phagocytosis in a cholesterol-
independent manner, being rescued only by MEV but not
cholesterol. The disparity in the effects of simvastatin on
molecular and functional outputs suggests that changes in
microglial activity after statin treatment are the result of
two distinct and separable molecular mechanisms.
Statin treatment alters the release profile of microglia
Treatment of isolated microglia resulted in differential ef-
fects on many of the released effectors, in a manner which
could alternately be interpreted as either inflammatory or
Figure 4 Cholesterol depletion and augmentation altered both phagocytosis and the release of Il1β, TNFα, and BDNF from microglia.
Isolated rat microglial cultures were treated with 4 mM mβcd for 30 min, washed and allowed to rest 30 min, then treated with 1 mM hpβcd-
cholesterol for 30 min, washed and allowed to rest 30 min. Cultures were activated with 1 μg/ml LPS overnight (18 h) and media was collected
and assayed for release of Il1β (A), TNFα (B), and BDNF (C). All analyses were normalized to the total protein of the corresponding cell lysate to
control for cell viability. Phagocytosis was assayed after cholesterol depletion (D-E) as in Figure 3. Dagger represents P <0.05 by Mann–Whitney
U-test while asterisks represent P <0.05, 0.01, and 0.001 by 2-way ANOVA with Bonferroni’s post-hoc from N = 3 independent preparations.
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sidered to be a pro-inflammatory cytokine, after simva-
statin treatment in ramified or surveilling, but not
activated, microglia (Figure 1D) can be interpreted as
anti-inflammatory, and the observed increase in BDNF
release (a potent neurotrophin and neuroprotectant)
from LPS-activated cells after simvastatin treatment
would likely be trophic in the brain. Similar reductions
in Il1β were observed after lovastatin treatment on rat
primary microglia [40] and in vivo in a rat model of
simvastatin treatment following traumatic brain injury
[37], though a recent study found simvastatin treatment
increased secretion of Il1β from isolated primate microglia
[42]. In contrast, TNFα secretion is increased in simva-
statin treated microglia in a cholesterol-dependent man-
ner. TNFα signalling through CD120 can result in toxiceffects by downstream activation of apoptosis through
caspase 8 cleavage, or survival effects by anti-apoptotic
activation through nuclear factor κ-B (NFκB) and c-Jun
N-terminal kinase (JNK) signalling. In this regard in-
creased secretion of TNFα from activated microglia
may either promote neuronal survival or contribute to
neurotoxicity. Several studies reported increases in TNFα
levels following statin treatment both in vitro and in vivo:
TNFα levels increased with simvastatin treatment of cul-
tured primate microglia [42], simvastatin or mevastatin
treatment increased TNFα levels in ex vivo hippocampal
slices [43], and TNFα levels were increased in perilesional
tissue following TBI and simvastatin treatment [37]. Com-
parable increases in TNFα were seen in human blood de-
rived macrophage cultures treated with simvastatin [24].
To our knowledge this is the first study to demonstrate
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following simvastatin treatment.
Simvastatin affects secretion through cholesterol-
dependent mechanisms
Following simvastatin treatment, most of the observed
changes in secretory profile were reversed by directly
supplementing microglia with cholesterol. The increased
release of both TNFα and BDNF from LPS-activated,
simvastatin treated microglia was reversed by treatment
with hpβcd-cholesterol, returning mean cellular choles-
terol to levels at or above that of controls (Figure 1A, B).
TNFα release from simvastatin-treated microglia was
also attenuated by treatment with MEV, which is ex-
pected as mevalonic acid is the immediate product of
HMG-CoA reductase and acts as the precursor to both
sterol and isoprenoid biosynthesis. These changes
strongly suggest that simvastatin affects microglial se-
cretion through a cholesterol-dependent mechanism,
rather than through a mechanism mediated by isopre-
noids. Two prior studies offer conflicting interpreta-
tions regarding this mechanism: in primate microglial
cultures TNFα release was found to be cholesterol-
dependent [42]; in rat hippocampal slices TNFα levels
reverted to control after MEV treatment or treatment
with geranylgeranyl pyrophosphate, the first committed
intermediate in isoprenoid biosynthesis [43], though a
role for cholesterol was not directly tested, the ex vivo
system precludes resolution of cell-specific effects. In a
comparable study on peripheral immune cells, an ob-
served increase in TNFα release from simvastatin treated
human blood derived macrophages was reversed by MEV
treatment, but as in the aforementioned study, a direct
role of cholesterol was not tested [24]. As release of NO
from LPS-activated microglia was unaffected by any of the
treatments used in this study (Figure 1C and further data
not shown), we can speculate that neither simvastatin
treatment nor cholesterol-depletion with mβcd affect acti-
vation of microglia through Toll-like receptor 4 (TLR4)
mediated activation of NFκB, as such a mechanism would
be expected to affect the expression of inducible nitric
oxide synthetase (iNOS).
To our knowledge, this is the first report to demon-
strate changes in Il1β secretion from primary microglia
following direct manipulation of cholesterol, though a
comparable increase in Il1β secretion was observed after
mβcd treatment of the immortalized microglial BV-2 cell
line [48]. In our assays an inverse correlation was ob-
served between directly manipulated cholesterol levels
and Il1β release: decreasing cholesterol resulted in in-
creased Il1β release, while increasing cholesterol mark-
edly decreased Il1β release even after stimulation with
the potent TLR4 agonist, LPS (Figures 1D and 4A).
Curiously, while decreasing cholesterol through statintreatment resulted in lower Il1β levels (Figure 1D), dir-
ectly decreasing cellular cholesterol content through
mβcd treatment resulted in an increase in Il1β with or
without LPS-activation (Figure 4A). This discrepancy
may be explained by one of two models. First, Il1β re-
lease may be affected by two distinct mechanisms – one
sensitive to cholesterol in the plasma membrane, and
one sensitive to intracellular cholesterol. Simvastatin acts
on HMG-CoA reductase, an enzyme localized primarily
to the endoplasmic reticulum [49], and so reduces chol-
esterol from the ‘inside-out’, likely resulting in changes
in cholesterol in intracellular compartments followed by
later changes in plasma membrane cholesterol. Con-
versely, mβcd acts directly on the extracellular leaflet of
the plasma membrane (PM), reducing cholesterol from
the ‘outside-in’, rapidly affecting PM cholesterol, which
subsequently equilibrates across membrane leaflets rap-
idly, but is then transported into intracellular compart-
ments by relatively slow trafficking through vesicles or
carrier proteins. A second interpretation of these data
would require a distinct isoprenoid-dependent mechan-
ism affecting Il1β release from statin-treated microglia.
In either scenario the observed decreased release of Il1β
from simvastatin-treated, LPS-activated microglia after
hpβcd-cholesterol treatment may represent the PM
cholesterol-dependent mechanism masking the contri-
bution of subtler cholesterol- or isoprenoid-dependent
mechanisms. The sensitivity to PM cholesterol is con-
sistent with observations that, unlike TNFα and BDNF,
Il1β secretion is dependent on the non-canonical path-
way of cytokine secretion. TNFα and BDNF are traf-
ficked in conventional ER- and Golgi-derived vesicles (as
a membrane bound pro-cytokine in the case of TNFα
and in dense-core vesicles for BDNF) while Il1β is syn-
thesized in the cytoplasm and is secreted either though
budding of microvesicles from the PM or possible trans-
port through specific PM resident transporters (eloquently
reviewed in [50]). This non-canonical secretory pathway is
likely to be differentially sensitive to the lipid composition
of the PM than conventional Golgi trafficking, as choles-
terol affects membrane fluidity and curvature (as required
for vesicular budding) [51-53] as well as regulating protein
activity through lipid microdomains (as may affect mem-
brane resident transporters) [54-56]. As such, we propose
that the observed sensitivity of Il1β release to cholesterol,
in particular the marked decrease in Il1β release from
LPS-activated microglia treated with hpβcd-cholesterol
(Figure 1D, 4A), may result from a blockade of the late re-
lease steps of Il1β. However, as a detailed mechanistic ana-
lysis of Il1β secretion was not the objective of this study
further analysis will be explored in future works. The in-
crease in basal secretion in the simvastatin control groups
can be attributed to the use of an ethanolic vehicle for de-
livery of simvastatin. As ethanol is itself a TLR4 agonist
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(<0.005%), the vehicle resulted in slightly higher Il1β se-
cretion as compared to an untreated control (compare
Figures 1D, 2, 3 and Figure 4A). We do not consider this
to be a significant confound as the vehicle effect was
slight, relative to potent TLR4 activation by LPS, and was
not found to affect any of the other measures reported
(TNFα, BDNF, NO, viability, or phagocytosis).
Simvastatin and mβcd inhibit phagocytosis through
distinct mechanisms
Both cholesterol lowering treatments tested in this study
reversibly inhibited phagocytosis of fluorescent latex
beads. Treatment of microglia with 2 mM mβcd signifi-
cantly reduced both the proportion of active phagocytes
and the mean uptake per phagocyte, both of which were
fully recovered after treatment with hpβcd-cholesterol
(Figure 4D-E). Simvastatin treatment comparably re-
duced both measures but phagocytosis was only recov-
ered with MEV, but not hpβcd-cholesterol treatment
(Figure 3A-B), suggesting a cholesterol-independent
mechanism. To our knowledge, this is the first report of
the effects of statins on phagocytosis in primary micro-
glia, though a study using the BV-2 cell line demon-
strated inhibition of amyloid-β induced phagocytosis
after simvastatin and lovastatin treatment [59]. Compar-
able studies of phagocytosis in cultured macrophages
have shown statin treatment was inhibitory in human
blood derived monocytes and macrophages [24,26], ro-
dent peritoneal macrophages [25], and in the immortal-
ized THP-1 macrophage cell line [60]. Kuipers and
colleagues [41] demonstrated inhibitory effects of statin
treatment on cytoskeletal dynamics and motility in pri-
mary microglial cultures – both of which would contrib-
ute to phagocytic mechanisms, but stopped short of
testing phagocytosis. Others report enhancement of
phagocytosis after statin treatment of rodent peritoneal
macrophages [28,29] and human blood derived mono-
cytes [27]. Reports are likewise mixed as to the mechan-
ism of statin mediated inhibition of phagocytosis, with
two showing rescue with cholesterol [25,28], two with
MEV alone [41,59], and one with MEV but not squalene,
the first committed intermediate in cholesterol synthesis
[24]. Our data suggest that phagocytosis in primary micro-
glia can be inhibited by cholesterol-dependent means
(demonstrated by mβcd treatment and recovery with chol-
esterol, Figure 4D-E) or by cholesterol-independent means
(demonstrated by simvastatin treatment and recovery only
by MEV, Figure 3A-B). As simvastatin was less effective at
depleting cholesterol than mβcd (at the doses we
tested) it remains possible higher simvastatin doses
would reveal a cholesterol-dependent component, though
such treatments may not represent relevant therapeutic
dosage [61].Separable mechanisms of statin action on microglia
Collectively, these data suggest statin treatment dir-
ectly affects the secretory profile of microglia and
microglial phagocytosis through two distinct mecha-
nisms. Simvastatin-dependent changes in the secretion
of cytokines and trophic factors were reversed by the
addition of exogenous cholesterol, suggesting a cholesterol-
dependent role in release, while simvastatin-dependent
changes in phagocytosis were reversed by co-treatment
with MEV but not through delivery of exogenous chol-
esterol, suggesting a cholesterol-independent role in
phagocytosis. This represents the first coupled analysis
of both the molecular and functional changes associ-
ated with statin treatment on primary cultured micro-
glia. Interestingly we can uncouple these two effects
through selective rescue, as simvastatin and cholesterol
treatment resulted in cells with ‘normal’ release of
TNFα and BDNF that remained phagocytosis-deficient.
These results may also help to explain conflicting re-
ports on the effects of statin treatment on cultured
microglia and macrophages – different markers of acti-
vation and secreted factors may be influenced by dis-
tinct signalling pathways with the same treatment.
While the field remains unsettled as to the mechanistic
contributions of cholesterol-dependent and independ-
ent components of statin therapy on pathological con-
ditions of the CNS, these data suggest there remains
room to improve the specificity of pharmacotherapy.
Ultimately, improved pharmacological agents will target
only those pathways that have the most direct impact




Dulbecco’s modified Eagle Medium/Ham’s F-12 (DMEM/F-
12, 1:1) was from Hyclone (Thermo-Fisher Scientific,
Ottawa, ON). Fetal bovine serum (FBS), normal horse serum
(NHS), penicillin/streptomycin, 0.25% trypsin/EDTA,
and Hank’s balanced saline solution (HBSS) were from
Gibco (Life Technologies, Burlington, ON). Simvastatin
was from Calbiochem (EMD Millipore, Billerica,
MA). Mevalonolactone, methyl-β-cyclodextrin, and
2-hydroxypropyl-β-cyclodextrin were from Sigma (Oakville,
ON). VectaShield mounting medium with 4’, 6-diamidino-
2-phenylindole (DAPI) was from Vector Labs (Burlington,
ON). All other reagents were of the highest quality
available.
Primary microglial cell culture and treatments
All animal procedures were carried out in accordance
with the guidelines of the University of Alberta Animal
Care Committee. Microglia were isolated from mixed
glial cultures at 14–21 days in vitro (d.i.v.) according to
Churchward and Todd Molecular Brain 2014, 7:85 Page 9 of 12
http://www.molecularbrain.com/content/7/1/85the method of Saura [62,63]. In brief, whole brains were
dissected from postnatal day one Sprague–Dawley rat
pups, meninges removed, and cells dissociated by trypsi-
nization and trituration. Mixed cultures were grown in
12-well plates coated with poly-L-lysine and maintained
in DMEM/F-12 with 10% FBS and 200 U/ml penicillin,
200 μg/ml streptomycin in a 37°C, 5% CO2 humidified
incubator. After reaching confluence, microglia were iso-
lated by mild trypsinization (0.25% trypsin/EDTA diluted
to 30% strength with DMEM/F12) for 20 minutes. Iso-
lated cultures were maintained in DMEM/F12 with 1%
FBS and 200 U/ml penicillin, 200 μg/ml streptomycin
for the duration of the experiment. Purity of microglial
isolations was routinely assessed by immunofluorescence
microscopy for microglia-specific markers (Iba1 or CD68)
compared to total nuclear staining with DAPI and was
consistently ≥98% microglia.
Treatments were carried out 24 h after isolation.
Simvastatin was first hydrolysed from the stable lactone
to the bioactive free acid in alkali ethanol followed by
neutralization with 1 N HCl. Mevalonolactone (MEV, the
lactone isomer of mevalonic acid) was delivered from
aqueous preparations. Cholesterol was delivered using
2-hydroxypropyl-β-cyclodextrin as vehicle [52,64]. All
treatments were carried out against an appropriate vehicle
control.
Molecular analyses
Nitric oxide levels were estimated by measuring the major
metabolite nitrite using the Griess reaction [65,66]. Chol-
esterol was assayed using an enzymatic Amplex Red assay
(Life Technologies, Burlington, ON) according to the
manufacturer’s instructions.
Enzyme-linked immunosorbant assays (ELISA) for
TNFα and Il1β were performed according to the manu-
facturer’s instructions (R&D Systems, Minneapolis, MN),
while BDNF was analysed by competitive ELISA. Briefly,
media samples or BDNF standards in 96-well plates were
incubated in coating buffer (100 mM Na2CO3, 10 mM
NaHCO3, pH 9.6) with goat anti-BDNF antibody
(1:100, Santa Cruz Biotechnology, Dallas, TX) overnightTable 1 Antibodies used for immunocytochemistry
Antigen Host
Ionized Ca2+-binding protein 1 (Iba1) Rabbit
CD68 (ED-1 clone) Mouse
Glial fibrillary acidic protein (GFAP) Mouse
GFAP Rabbit
Mouse-Alexa Fluor 488 conjugate Donkey
Rabbit-Alexa Fluor 488 conjugate Donkey
Mouse-Alexa Fluor 647 conjugate Donkey
Rabbit-Alexa Fluor 647 conjugate Donkeyat 4°C. Plates were washed 3x with phosphate buffered
saline +0.05% Tween-20 (PBS-T) and blocked with 1%
BSA in PBS for 2 h at room temperature. After wash-
ing, plates were incubated with a biotin-conjugated
anti-goat secondary antibody (1:2000 in PBS +1% BSA)
for 1 h, followed by horseradish peroxidase-conjugated
streptavidin (1:200 in PBS +1% BSA) for 20 minutes.
Colour was developed by adding tetramethylbenzidine
(0.027% in 100 mM sodium acetate, 19 mM citric acid,
40% methanol, and 0.3% H2O2) for 20 minutes at room
temperature. Assay development was stopped by the
addition of 1.8 N H2SO4 and measured at 450 nm with
correction at 570 nm.
Viability was routinely assessed for all treatment condi-
tions by incubation with 0.5 mg/ml 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) for 30 min
and measurement of the oxidized formazan end-product at
540 nm.
All molecular analyses were normalized to the protein
level of the cell lysate, measured using the BCA assay
(Thermo-Fisher Pierce, Ottawa, ON) to account for any
variability in cell numbers between wells.Immunocytochemistry
At the end of treatment, cells were washed 3x with
HBSS supplemented with 1 mM Ca2+ and 0.5 mM Mg2+
and fixed in 5% PBS-buffered formalin for 10 minutes at
room temperature. Each of the following sequential
steps was preceded by washing 3x with PBS: fixed cells
were blocked and permeablized (PBS supplemented with
1% NHS and 0.1% triton X-100 for 1 h), incubated with
primary antibody (dilutions as indicated in Table 1 in
PBS with 0.1% NHS, overnight at 4°C), incubated with
Alexa conjugated secondary antibody (dilutions as indi-
cated in Table 1 in PBS with 0.1% NHS, 2 h at room
temperature), and mounted using Vectashield with DAPI.
Images were acquired using a Leica AF6000-LX micro-
scope. Confocal microscopy was performed on a Leica
TCS-SPE inverted microscope. Post-processing was per-
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Phagocytosis was assayed by incubating treated cells
with 1x107 green fluorescent 1 μm carboxylate-modified
latex beads (Sigma, Oakville, ON) per well for 3 h. Cells
were then processed for immunocytochemistry as above
with CD68 as a marker for microglia and DAPI as a nu-
clear stain. Images were acquired according to a defined
grid (21 images per well) to reduce user bias and ana-
lyzed automatically using macros custom written for
ImageJ. Briefly, total cells were identified by nuclear
staining and a region of interest (ROI) was defined to
enclose the cell soma. Fluorescence was integrated for
green (GFP filters, beads) and red channels (CY5 filters,
CD68 immunofluorescence) within the somatic ROI.
CD68 immunofluorescence was used to validate culture
purity. A subset of images was randomly selected to
manually validate the results of automated analysis.
Total phagocytes are reported as the proportion of cells
per well that took up at least 1 bead, while cellular
phagocytic activity was defined as the mean integrated
fluorescence of cells that had taken up at least 1 bead.
Statistical analyses
Overall significance was assessed using 2-way analysis of
variance, with Bonferroni’s multiple comparison post-
hoc analysis between groups. Pairwise comparisons
were assessed using a Mann–Whitney U test. A P value
of ≤0.05 was considered significant. Data are presented
as the mean ± SEM. Each reported N indicates an inde-
pendent experiment from a separate culture preparation.
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